Form 4: Oramed Pharmaceuticals CEO Nadav Kidron Acquires Shares Through Performance Stock Unit Vesting

Nadav Kidron, CEO of Oramed Pharmaceuticals, acquired a total of 427,000 shares of common stock on February 11, 2025, through the vesting of performance stock units (PSUs).

Summary

• Nadav Kidron, the CEO of Oramed Pharmaceuticals, reported the acquisition of 427,000 shares of common stock on February 11, 2025.
• These shares were obtained through the settlement of performance stock units (PSUs) that vested on the same date.
• The PSUs were previously granted on January 4, 2024 (141,000 shares), January 2, 2025 (186,000 shares), and February 3, 2025 (100,000 shares).
• The vesting of these PSUs was contingent upon the achievement of specific performance criteria.
• Following these transactions, Kidron directly owns 2,686,598 shares of Oramed Pharmaceuticals' common stock and indirectly owns 126,000 shares through a wholly-owned corporation.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs indicates that performance targets were met, which is a positive sign. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The vesting of performance stock units suggests that the company has met certain performance targets.
• The CEO's increased stake in the company could be interpreted as a sign of confidence in Oramed's future prospects.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency into the holdings of company executives. It is common for executives to receive stock-based compensation, and the vesting of these awards is typically tied to performance metrics.

Stakeholder Impact

• The increased ownership by the CEO could be viewed positively by shareholders.

Key Dates